Tim Mayleben
President & Chief Executive Officer
Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010. Prior
to joining Esperion, Tim was President, CEO and a Director of Aastrom Biosciences, Inc. (NASDAQ: ASTM). Previously, Tim was
President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the COO
of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of
several life science companies, including DeNovo Sciences, Intelliject Corporation, Lycera Corporation and Marinus Pharmaceuticals.
Tim earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a
B.B.A. from the University of Michigan, Ross School of Business.
Roger Newton
Executive Chairman & Chief Scientific Officer
Roger Newton is founder, Executive Chairman and Chief Scientific Officer of Esperion and is a fellow of the American Heart
Association. Prior to founding Esperion in 2008, Roger was Senior Vice President, Pfizer Global R&D from 2004 to 2008. Previously,
Roger was Co-founder, President & CEO of the original Esperion from July 1998 until its acquisition by Pfizer in 2004. Prior to
founding the original Esperion, Roger was Chairman of the Atherosclerosis Drug Discovery Team at Warner Lambert from 1981 to
1998. Roger is a director of a number of life science companies including Juventas Therapeutics, Inc. and Rubicon Genomics, Inc.
and is also a member of the Technology Advisory Boards for Arboretum Ventures and Metagenics, Inc. Roger earned a Ph.D. in
Nutrition from the University of California, Davis, an M.S. in Nutritional Biochemistry from the University of Connecticut, and a B.S. in
Biology from Lafayette College.
Narendra Lalwani
Executive Vice President, Research & Development, Chief Operating Officer
Narendra Lalwani is Executive Vice President, R & D, and Chief Operating Officer. Prior to joining Esperion, Narendra was Chief
Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Narendra was
Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer. Prior to Esperion, Narendra held various positions
of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Narendra
is a Fellow of American Heart Association (FAHA) and a diplomate of the American board of Toxicology (DABT). Narendra earned a
Ph.D. in Biophysics from the University of Bombay (India) and an MBA from the University of Michigan, Ross School of Business.
Marianne Andreach
Vice President, Strategic Marketing & Product Planning
Marianne Andreach is Vice President of Strategic Marketing and Product Planning. Prior to joining Esperion, Marianne was a
consultant in the pharmaceutical industry. Previously, she was Senior Director, Business Development and Team Lead, MDCO-216
(ApoA-I Milano) at The Medicines Company. Marianne also worked in Medical Affairs at Pfizer Global R&D, and led Marketing and
Product Planning at the original Esperion Therapeutics. Additionally, Marianne has worked in a variety of marketing and product
planning roles at Bristol-Myers Squibb and Parke-Davis, including working on the launch teams for both Pravachol and Lipitor, as well
as supporting both Plavix and Glucophage. Marianne earned a BA in Biology/History from the College of the Holy Cross.